U.S. Food and Drug Administration Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 ≥1%

PRINCETON, N.J.--(BUSINESS WIRE) May 15, 2020 --Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) was approved by the U.S. Food and Drug Administration...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news